Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AXSM Axsome Therapeutics, Inc. daily Stock Chart
AXSM [NASD]
Axsome Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.15 Insider Own2.10% Shs Outstand31.44M Perf Week8.06%
Market Cap471.91M Forward P/E- EPS next Y-0.93 Insider Trans1.62% Shs Float24.21M Perf Month24.98%
Income-31.00M PEG- EPS next Q-0.30 Inst Own17.60% Short Float15.86% Perf Quarter80.41%
Sales- P/S- EPS this Y9.40% Inst Trans57.05% Short Ratio3.34 Perf Half Y326.42%
Book/sh0.03 P/B500.33 EPS next Y2.10% ROA-152.60% Target Price28.25 Perf Year477.31%
Cash/sh0.45 P/C33.71 EPS next 5Y- ROE-582.20% 52W Range1.94 - 16.80 Perf YTD432.27%
Dividend- P/FCF- EPS past 5Y-56.60% ROI- 52W High-10.65% Beta3.50
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low673.71% ATR1.26
Employees29 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)61.48 Volatility9.44% 9.57%
OptionableYes Debt/Eq7.67 EPS Q/Q-4.70% Profit Margin- Rel Volume0.79 Prev Close14.90
ShortableYes LT Debt/Eq4.00 EarningsMar 14 BMO Payout- Avg Volume1.15M Price15.01
Recom1.50 SMA205.66% SMA5032.06% SMA200162.29% Volume902,849 Change0.74%
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Apr-17-19 07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 11:07AM  Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up Zacks +8.18%
Apr-15-19 06:00AM  Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation GlobeNewswire +6.32%
Apr-08-19 09:19AM  Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March Motley Fool
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Apr-03-19 08:50AM  Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options Zacks
Mar-30-19 12:00PM  3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop Motley Fool
Mar-28-19 06:10PM  Axsome's Depression Drug Gets Breakthrough Therapy Status Zacks
09:49AM  3 Small Biotech Stocks Hitting New Highs Investopedia
07:27AM  Jim Cramer Weighs In On General Electric, Nio, Sprint And More Benzinga
Mar-27-19 08:22AM  UPDATE: Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug MarketWatch
07:00AM  Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder GlobeNewswire
Mar-25-19 02:15PM  Here's Why Axsome Therapeutics' Stock Gained as Much as 22.9% Today Motley Fool +25.69%
11:51AM  Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year? Simply Wall St.
Mar-22-19 11:39AM  Harry Boxer: 3 biotech stocks with momentum MarketWatch
Mar-14-19 07:26AM  Axsome: 4Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update GlobeNewswire
Mar-07-19 06:03AM  2 Biotech Stocks With Major Incoming Catalysts Motley Fool
Mar-06-19 07:00AM  Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank GlobeNewswire
Mar-05-19 07:00AM  Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 GlobeNewswire
Mar-04-19 07:00AM  Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine GlobeNewswire
Feb-06-19 07:00AM  Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine GlobeNewswire -5.42%
Jan-30-19 07:00AM  Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy GlobeNewswire
Jan-15-19 08:00PM  3 Small-Cap Stocks With Big-Cap Potential Motley Fool
Jan-10-19 01:38PM  Is This Why Axsome Therapeutics Is Losing Ground Again Today? Motley Fool
Jan-09-19 07:00AM  Market Rally Extends to Biotech ACCESSWIRE -14.98%
06:30AM  This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads? ACCESSWIRE
Jan-08-19 12:38PM  Here's Why Axsome Therapeutics Has Been a Rocket Ship This Week Motley Fool +29.26%
10:17AM  Axsome Therapeutics: Do Not Buy AXSM Stock After Its Monster Rally InvestorPlace
09:15AM  Portfolios Making Up For Lost Time Zacks
08:30AM  The Next Big Biotech Breakout ACCESSWIRE
08:15AM  The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase Benzinga
Jan-07-19 06:35PM  Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility GlobeNewswire +161.22%
01:28PM  AXSM News: Why Axsome Therapeutics Stock Is Skyrocketing Today InvestorPlace
12:25PM  4 Healthcare Stocks Making Moves On Monday (1/7/19) ACCESSWIRE
08:25AM  Tiny Pharma Company Surges 160% on Positive Depression Drug Data Bloomberg
08:23AM  Axsome's stock nearly triples on heavy volume after positive trial of depression treatment MarketWatch
06:00AM  Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder GlobeNewswire
Dec-31-18 01:50PM  These 4 Healthcare Stocks May Test December Highs ACCESSWIRE +29.36%
07:25AM  New Research: Key Drivers of Growth for Trimble, Maxar Technologies, MagnaChip Semiconductor, Palo Alto Networks, AAR, and Axsome Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Dec-27-18 10:25AM  These 4 Healthcare Stocks Are Gaining Speed ACCESSWIRE
07:00AM  Axsome Therapeutics Provides Year End 2018 Clinical Update GlobeNewswire
Dec-18-18 07:00AM  Axsome Therapeutics to Present at Biotech Showcase 2019 GlobeNewswire
Dec-11-18 06:55AM  Today's Research Reports on Trending Tickers: Axsome Therapeutics and Avid Bioservices ACCESSWIRE
Dec-10-18 08:25AM  UPDATE: Axsome Therapeutics shares soar 24% premarket on positive trial of Alzheimer's therapy MarketWatch +14.92%
07:00AM  Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimers Disease Agitation GlobeNewswire
Nov-27-18 07:00AM  Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate GlobeNewswire
Nov-21-18 08:50AM  Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-19-18 07:00AM  Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference GlobeNewswire +9.22%
Nov-14-18 07:00AM  Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire
Nov-09-18 07:42AM  Axsome: 3Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Nov-01-18 07:00AM  Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018 GlobeNewswire
Oct-18-18 07:00AM  Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimers Disease Agitation GlobeNewswire
Oct-17-18 07:00AM  Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy GlobeNewswire +11.36%
Oct-16-18 07:05AM  Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy GlobeNewswire +5.07%
07:00AM  Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy GlobeNewswire
Oct-12-18 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Oct-11-18 07:00AM  Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets GlobeNewswire
Sep-28-18 07:00AM  Axsome Therapeutics Announces $8.9 Million Registered Direct Offering GlobeNewswire
Sep-26-18 03:57PM  What Does Axsome Therapeutics Incs (NASDAQ:AXSM) Ownership Structure Look Like? Simply Wall St.
Sep-24-18 07:00AM  Axsome Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-19-18 07:00AM  Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimers Disease Agitation GlobeNewswire
Aug-28-18 07:00AM  Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +18.81%
Aug-08-18 07:40AM  Axsome: 2Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
06:00AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:00AM  Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018 GlobeNewswire
Jul-17-18 07:00AM  Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimers Association International Conference GlobeNewswire
Jun-05-18 07:00AM  Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder GlobeNewswire +5.88%
May-29-18 07:00AM  Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting GlobeNewswire
May-22-18 07:00AM  Axsome Therapeutics to Present at the 2018 BIO International Convention GlobeNewswire
May-08-18 10:43AM  Is Axsome Therapeutics Incs (NASDAQ:AXSM) CEO Incentives Align With Yours? Simply Wall St.
09:24AM  Axsome: 1Q Earnings Snapshot Associated Press
07:00AM  Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
06:15AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-18 07:00AM  Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association GlobeNewswire
May-01-18 07:00AM  Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-26-18 07:00AM  Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression GlobeNewswire +13.21%
Apr-25-18 07:30AM  Wired News Axsome Therapeutics Initiated Phase-2 Clinical Trial of AXS-05 in Smoking Cessation ACCESSWIRE
Apr-24-18 07:00AM  Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimers Disease Agitation, and Nicotine Dependence GlobeNewswire
Apr-23-18 07:00AM  Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation GlobeNewswire
Apr-19-18 08:18PM  Should You Be Concerned About Axsome Therapeutics Incs (NASDAQ:AXSM) Investors? Simply Wall St.
07:00AM  Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer GlobeNewswire
Apr-11-18 07:00AM  Axsome Therapeutics to Participate in the Leerink Partners 2018 CNS Day GlobeNewswire
Mar-27-18 07:00AM  Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimers Disease Agitation, and Nicotine Dependence GlobeNewswire
Mar-26-18 07:00AM  Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire
Mar-19-18 07:00AM  Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-12-18 07:00AM  Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics GlobeNewswire
Mar-07-18 07:20AM  Axsome reports 4Q loss Associated Press
07:00AM  Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
06:00AM  Axsome Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-18 07:00AM  Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 GlobeNewswire
Feb-26-18 08:20AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
07:00AM  Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan GlobeNewswire
Feb-14-18 07:29PM  Is Axsome Therapeutics Incs (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Feb-05-18 07:00AM  Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference GlobeNewswire
Jan-10-18 09:17AM  Heres Whats Moving Axsome Therapeutics and Pain Therapeutics Market Exclusive
08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-09-18 07:00AM  Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial GlobeNewswire -36.04%
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorMar 19Buy12.185,10062,1185,100Mar 21 07:05 AM
Pizzie NickChief Financial OfficerMar 19Buy12.696076160Mar 21 07:05 AM
Pizzie NickChief Financial OfficerMar 19Buy12.585,34067,17736,340Mar 21 07:05 AM
Pizzie NickChief Financial OfficerJun 19Buy3.1031,00096,08031,000Jun 20 05:00 PM
open in yahoo | open in reuters | open in google